Cargando…

Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada

The dataset covers the equations and procedure used for the estimation of an older adult's total annual medication costs, across Canadian provinces and territories; detailed to report pharmacy margin, government share, and patient share. We presented a case of an older adult using 10 different...

Descripción completa

Detalles Bibliográficos
Autores principales: Fadaleh, Sarah Abu, Shkrobot, Jody, Makhinova, Tatiana, Eurich, Dean, Sadowski, Cheryl A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327419/
https://www.ncbi.nlm.nih.gov/pubmed/32637472
http://dx.doi.org/10.1016/j.dib.2020.105842
_version_ 1783552540463333376
author Fadaleh, Sarah Abu
Shkrobot, Jody
Makhinova, Tatiana
Eurich, Dean
Sadowski, Cheryl A.
author_facet Fadaleh, Sarah Abu
Shkrobot, Jody
Makhinova, Tatiana
Eurich, Dean
Sadowski, Cheryl A.
author_sort Fadaleh, Sarah Abu
collection PubMed
description The dataset covers the equations and procedure used for the estimation of an older adult's total annual medication costs, across Canadian provinces and territories; detailed to report pharmacy margin, government share, and patient share. We presented a case of an older adult using 10 different medications commonly used, according to Canadian Institute for Health Information. Eight different deprescribing scenarios were created, based on recommendations from Beers Criteria and the Canadian Deprescribing Network, for the purpose of comparing the cost difference before and after each intervention on pharmacies, patients, and governments. Scenarios included: (1) Stopping an over the counter medication; (2) Discontinuation of a medication; (3) Slow taper of a potentially inappropriate medication; (4) Rapid taper of a potentially inappropriate medication; (5) Switching to safer medication; (6) Dose reduction; (7) Switching to a lower cost medication; (8) Changing from combination to a single medication. The data presented are related to the article entitled “Financial advantage or barrier when deprescribing for seniors: A case based analysis” [1]
format Online
Article
Text
id pubmed-7327419
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73274192020-07-06 Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada Fadaleh, Sarah Abu Shkrobot, Jody Makhinova, Tatiana Eurich, Dean Sadowski, Cheryl A. Data Brief Pharmacology, Toxicology and Pharmaceutical Science The dataset covers the equations and procedure used for the estimation of an older adult's total annual medication costs, across Canadian provinces and territories; detailed to report pharmacy margin, government share, and patient share. We presented a case of an older adult using 10 different medications commonly used, according to Canadian Institute for Health Information. Eight different deprescribing scenarios were created, based on recommendations from Beers Criteria and the Canadian Deprescribing Network, for the purpose of comparing the cost difference before and after each intervention on pharmacies, patients, and governments. Scenarios included: (1) Stopping an over the counter medication; (2) Discontinuation of a medication; (3) Slow taper of a potentially inappropriate medication; (4) Rapid taper of a potentially inappropriate medication; (5) Switching to safer medication; (6) Dose reduction; (7) Switching to a lower cost medication; (8) Changing from combination to a single medication. The data presented are related to the article entitled “Financial advantage or barrier when deprescribing for seniors: A case based analysis” [1] Elsevier 2020-06-08 /pmc/articles/PMC7327419/ /pubmed/32637472 http://dx.doi.org/10.1016/j.dib.2020.105842 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Pharmacology, Toxicology and Pharmaceutical Science
Fadaleh, Sarah Abu
Shkrobot, Jody
Makhinova, Tatiana
Eurich, Dean
Sadowski, Cheryl A.
Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada
title Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada
title_full Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada
title_fullStr Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada
title_full_unstemmed Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada
title_short Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada
title_sort dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in canada
topic Pharmacology, Toxicology and Pharmaceutical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327419/
https://www.ncbi.nlm.nih.gov/pubmed/32637472
http://dx.doi.org/10.1016/j.dib.2020.105842
work_keys_str_mv AT fadalehsarahabu datasetoncostanalysisofmedicationdeprescribingscenariosforolderadultcoverageunderpublicdrugbenefitprogramsincanada
AT shkrobotjody datasetoncostanalysisofmedicationdeprescribingscenariosforolderadultcoverageunderpublicdrugbenefitprogramsincanada
AT makhinovatatiana datasetoncostanalysisofmedicationdeprescribingscenariosforolderadultcoverageunderpublicdrugbenefitprogramsincanada
AT eurichdean datasetoncostanalysisofmedicationdeprescribingscenariosforolderadultcoverageunderpublicdrugbenefitprogramsincanada
AT sadowskicheryla datasetoncostanalysisofmedicationdeprescribingscenariosforolderadultcoverageunderpublicdrugbenefitprogramsincanada